AMCP Statement on White House Prescription Drug Pricing Executive Orders

Alexandria, Va., July 24, 2020 — This afternoon, the Trump administration released executive orders focused on pharmaceutical pricing. In response, AMCP CEO Susan A. Cantrell, RPh, CAE, released the following statement:  

“AMCP and our members join Americans across the country in their significant concern about the rising costs of pharmaceuticals, magnified by a global pandemic. Costliness and high unemployment have resulted in health care being out of reach for millions of American families, and it's clear it is time for elected leaders to prioritize solving this crisis.

“We will continue to work with elected officials and health care stakeholders to develop practical, informed, and market-based solutions that make health care and prescription drugs more affordable and accessible to all Americans.”

### 

AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. 

AMCP advocates at the national and state level for developing and applying evidence-based medication use strategies that improve access to medication, enhance patient and population health outcomes, and safeguard the wise use of health care dollars. Visit www.amcp.org. 

Contact:  

Abigail Fredenburg 
@email 
703-684-2652